EDIT vs PTC · rev $32.3M vs P/E 48, rev $2.74B
Editas Medicine Inc (EDIT) versus PTC Inc (PTC) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
PTC Inc (PTC) is a software - application company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported PTC revenue for 2025-09-30 was $2.74B. Net income was $734.0M. Revenue was up 19.2% from 2024-09-30 to 2025-09-30. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
EDIT currently screens at market cap $375.2M. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
Not investment advice. Open the EDIT and PTC stock pages for the full models.
Not investment advice.